WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, reported its financial results for the first quarter ended March 31, 2017, and provided a business update. As of March 31, 2017, Radius had $282.1 million in cash, cash equivalents and marketable securities.
TYMLOS™ (abaloparatide)
On April 28, 2017, Radius announced that the U.S. Food and Drug Administration (FDA) approved TYMLOS™ (abaloparatide) injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. TYMLOS is the first new bone building therapy approved in nearly 15 years.
